Just under a year ago, Veritas Genetics announced it would be launching the first whole genome sequencing test with a price tag under $1,000. Now, the company is bringing on board a new vice president of clinical affairs to help lower the cost of that sequencing and improve the process of interpreting the results.
Birgit Funke has worked extensively on the genetic underpinnings of inherited heart diseases, including cardiomyopathies, and has also written about the racial disparities in genetic testing and research. As of February 1, Funke has split her time between the Danvers, Mass.-based spinoff of the non-profit Personal Genome Project and her work as an associate professor at Harvard Medical School and a researcher at Partners Personalized Medicine’s Laboratory of Molecular Medicine.
About the Author Reprints
